Arylosulfonamides for the treatment of cns diseases

A compound of the general formula (I)

• or pharmaceutically acceptable salt thereof,
• wherein
• E represents N, C or CH;
• represents single bond or double bond;
• n represents an integer from 2 to 6, inclusive;
• A represents a 9- or 10-membered bicyclic group, consisting of benzene ring fused with 5- or 6-membered heterocyclic ring, which group is linked to E through one of its carbon atoms and has the following formula (A):
• wherein
• X represents CR5, C(R5)2, NH or O;
• Z represents CR5, C(R5)2, or N;
• R5 represents hydrogen atom, halogen atom or C1-C4-alkyl;
• Y represents NH, O or S;
• each of R1, R2, R3 and R4 independently represents hydrogen atom or halogen atom;
• each of R6 and R7 independently represents hydrogen atom, halogen atom, or C5-C4-alkyl;
• or R6 and R5 together form carbonyl group ═O;
• represents single bond or double bond;
• m is 0 or 1;
• q is 0 or 1;
• wherein at least one of q and m is 1;
• D represents a group selected from:
• unsubstituted phenyl or phenyl substituted with one or more substituents independently selected from the group consisting of branched C1-C4-alkyl;
• straight C1-C4-alkyl in ortho or meta position with respect to sulphonamide group;
• C5-C3-alkyloxy;
• halogeno-C1-C3-alkyl;
• halogeno-C1-C3-alkyloxy;
• halogen atom;
• —CN;
• —OH;
• and phenyl;
• unsubstituted naphthyl or naphthyl substituted with one or more substituents independently selected from the group consisting of C1-C4-alkyl;
• C1-C3-alkyloxy;
• halogeno-C1-C3-alkyl;
• halogen atom;
• —CN;
• —OH;
• and phenyl;
• 5-membered aromatic heterocyclic group having 1 to 3 heteroatoms independently selected from the group consisting of N, O, S, the group being unsubstituted or substituted with one or more substituents independently selected from the group consisting of C1-C4-alkyl;
• C1-C3-alkyloxy;
• halogeno-C1-C3-alkyl;
• halogen atom;
• —CN;
• —OH;
• and phenyl;
• bicyclic group consisting of benzene or pyridine ring fused with 5-membered aromatic or non-aromatic heterocyclic ring having 1 to 3 heteroatoms independently selected from the group consisting of N, O, S, which group is unsubstituted or substituted with one or more substituents independently selected from the group consisting of C1-C4-alkyl;
• C1-C3-alkyloxy;
• halogeno-C1-C3-alkyl;
• halogen atom;
• ═O;
• —CN;
• —OH;
• and phenyl;
• bicyclic group consisting of benzene or pyridine ring fused with 6-membered non-aromatic heterocyclic ring having from 1 to 3 heteroatoms independently selected from the group consisting of N, O, S, which group is unsubstituted or substituted with one or more substituents independently selected from the group consisting of C1-C4-alkyl;
• C1-C3-alkyloxy;
• halogeno-C1-C3-alkyl;
• halogen atom;
• ═O;
• —CN;
• —OH;
• and phenyl;
• with the proviso that 3,4-dichloro-N-{[4-(1H-indol-3-yl)piperidin-1-yl]pentyl}benzene-sulphonamide and N-{4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl}benzene-sulphonamide and the salts thereof are excluded.